Previous Article | Next Article 
J Virol, July 1998, p. 5472-5480, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Characterization of Wild-Type Adeno-Associated Virus Type 2-Like
Particles Generated during Recombinant Viral Vector Production and
Strategies for Their Elimination
Xu-Shan
Wang,1,2,3
Benjawan
Khuntirat,1,2,3
Keyun
Qing,1,2,3
Selvarangan
Ponnazhagan,1,2,3
Dagmar M.
Kube,1,2,3
Shangzhen
Zhou,4
Varavani J.
Dwarki,4 and
Arun
Srivastava1,2,3,5,*
Department of Microbiology and
Immunology,1
Walther Oncology
Center,2 and
Division of
Hematology/Oncology, Department of Medicine,5
Indiana University School of Medicine, and
Walther Cancer
Institute,3 Indianapolis, Indiana 46202, and
Virology Department, Chiron Corporation, Emeryville, California
946084
Received 11 November 1997/Accepted 23 March 1998
 |
ABSTRACT |
The pSub201-pAAV/Ad plasmid cotransfection system was
developed to eliminate homologous recombination which leads to
generation of the wild-type (wt) adeno-associated virus type 2 (AAV)
during recombinant vector production. The extent of contamination with wt AAV has been documented to range between 0.01 and 10%. However, the
precise mechanism of generation of the contaminating wt AAV remains
unclear. To characterize the wt AAV genomes, recombinant viral
stocks were used to infect human 293 cells in the presence of
adenovirus. Southern blot analyses of viral replicative DNA intermediates revealed that the contaminating AAV genomes were not
authentic wt but rather wt AAV-like sequences derived from recombination between (i) AAV inverted terminal repeats (ITRs) in the
recombinant plasmid and (ii) AAV sequences in the helper plasmid. Replicative AAV DNA fragments, isolated following
amplification through four successive rounds of amplification in
adenovirus-infected 293 cells, were molecularly cloned and subjected to
nucleotide sequencing to identify the recombinant junctions. Following
sequence analyses of 31 different ends of AAV-like genomes derived from two different recombinant vector stocks, we observed that all recombination events involved 10 nucleotides in the AAV D sequence distal to viral hairpin structures. We have recently documented that
the first 10 nucleotides in the D sequence proximal to the AAV hairpin
structures are essential for successful replication and
encapsidation of the viral genome (X.-S. Wang et al., J. Virol. 71:3077-3082, 1997), and it was noteworthy that in each recombinant junction sequenced, the same 10 nucleotides were retained. We also
observed that adenovirus ITRs in the helper plasmid were involved
in illegitimate recombination with AAV ITRs, deletions of which
significantly reduced the extent of wt AAV-like particles. Furthermore,
the combined use of recombinant AAV plasmids lacking the distal 10 nucleotides in the D sequence and helper plasmids lacking the
adenovirus ITRs led to complete elimination of replication-competent wt
AAV-like particles in recombinant vector stocks. These strategies should be useful in producing clinical-grade AAV vectors suitable for
human gene therapy.
 |
INTRODUCTION |
Adeno-associated virus type 2 (AAV) is a nonpathogenic human parvovirus which contains
a single-stranded, linear DNA genome of 4,680 nucleotides
(45). AAV is dependent on coinfection with a helper virus,
such as adenovirus or herpesvirus, for its optimal replication (3,
4), but in the absence of a helper virus, the wild-type (wt) AAV
genome integrates into the host chromosome in a site-specific manner
and establishes a latent infection (18-20, 39). Three
elements of the AAV genome are required for the viral replicative life
cycle. The first is a pair of inverted terminal repeats (ITRs) which
fold into hairpin structures, and the 3' end serves as a primer for AAV
DNA replication (12, 23, 35, 38, 43). ITRs are also required
for AAV genome encapsidation and integration (10, 38, 47).
The second is the rep gene which codes for four viral
replication (Rep) proteins (4, 5, 26). Rep proteins are also
required for viral gene expression, DNA encapsidation, and
site-specific integration (2, 5-8, 14-16, 21, 24, 25, 35,
40). And the third is the cap gene which encodes the
viral capsid (Cap) proteins required for viral assembly (35,
45). ITRs are the sole cis-acting sequences required
for viral DNA replication, encapsidation, and integration (37). Based on the fact that AAV is a nonpathogenic human
parvovirus that can infect both dividing and nondividing cells (8,
30), and that it can stably integrate into the host chromosome,
recombinant AAV vectors have been developed as a potentially useful
alternative to the more commonly used retrovirus and adenovirus vectors
for human gene therapy (4, 9, 26, 37, 41, 44, 44a).
The production of recombinant AAV utilizes a vector containing a
transgene cassette flanked by the viral ITRs. Recombinant vectors are
generated by cotransfecting the recombinant AAV plasmid and a helper
plasmid into adenovirus-infected cells (36, 37). The helper
plasmid contains the AAV rep and cap genes which
provide Rep and Cap proteins in trans, respectively,
required for efficient rescue of the recombinant AAV genome from the
recombinant plasmid, followed by replication and encapsidation into
progeny virions. Rescue, replication, and packaging of the AAV genome
do not occur from the helper plasmid which lacks the AAV ITR. However,
several reports have documented that wt AAV particles are also
generated during recombinant AAV vector production (11, 17, 21,
26, 33, 42), but the underlying mechanism of generation of the wt
AAV remains unknown. Whether the contaminating AAV is truly authentic
wt AAV or whether these particles originate following recombination
between the recombinant AAV and the helper plasmids also remains
unclear. In pursuit of answers to these questions, we have carried out
systematic analyses of the wt AAV genomes molecularly cloned from two
different recombinant AAV vector stocks. Our data indicate that (i) the
contaminating AAV is not authentic wt AAV but rather wt AAV-like, (ii)
wt AAV-like particles are generated by nonhomologous recombination
between the recombinant AAV and the helper plasmids, (iii) adenovirus
ITRs in the helper plasmid contribute to generation of these particles,
(iv) the recombinant sites in the AAV ITRs are crowded around the
distal 10 nucleotides in the D sequence, and (v) removal of the
adenovirus ITRs from the helper plasmid and deletion of the distal 10 nucleotides in the D sequence from the recombinant plasmid lead to
elimination of replication-competent wt AAV-like particles.
 |
MATERIALS AND METHODS |
Cells, viruses, and plasmids.
The human embryonic kidney
cell line 293 was obtained from the American Type Culture Collection
(Rockville, Md.), and the human nasopharyngeal carcinoma cell line KB
was obtained from Asok C. Antony, Indiana University School of
Medicine, Indianapolis. Cells were maintained as monolayer cultures in
Iscove's modified Dulbecco's medium supplemented with 10% fetal
bovine serum, penicillin, and streptomycin as previously described
(27). The human adenovirus type 2 (Ad2) stock was obtained
from Kenneth H. Fife, Indiana University School of Medicine, and
propagated as previously described (28). The AAV helper
plasmid containing the AAV coding sequences flanked by the Ad5 ITRs,
pAAV/Ad (37), was supplied by Richard J. Samulski,
University of North Carolina, Chapel Hill. An AAV helper plasmid
lacking the Ad5 ITRs, pSP-19, has been described previously
(48), and an additional AAV helper plasmid, pAAVp5, was
constructed such that the AAVp5 promoter sequences were inserted downstream of the polyadenylation signal of AAV as follows. A 693-bp
BalI-SacI DNA fragment containing the AAV p5
promoter sequences was isolated from plasmid pSub201
(36), digested with BbvI, and treated with the
Klenow fragment of Escherichia coli DNA polymerase I. A
203-bp BalI-BbvI fragment was recovered, digested
with XbaI, and ligated at the 3' end of the AAV genome in
plasmid pSP-19 partially digested with XbaI and completely
digested with SpeI. Each of these three helper plasmids is
shown schematically in Fig. 1.
Recombinant AAV plasmids pCMVp-lacZ, containing the human cytomegalovirus (CMV) immediate-early promoter-driven
-galactosidase gene (31, 32), and pWP-8A, containing the genes for
resistance to tetracycline and the herpesvirus thymidine kinase
promoter-driven gene for resistance to neomycin (29), have
also been described previously. The construction of plasmid pD-10,
which contains deletions in the distal 10 nucleotides in the D sequence
within the AAV ITRs, was described recently (49). The CMV
promoter-driven lacZ gene sequences were also inserted in
the pD-10 vector to generate a recombinant plasmid, pBK-2. Standard
cloning techniques were used for constructing all recombinant plasmids
(34).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the recombinant AAV helper
plasmids. The three viral promoters are marked by arrows, and the viral
rep and cap genes are represented by shaded and
cross-hatched boxes, respectively. The Ad ITRs are denoted by closed
boxes, and the plasmid vector backbones are indicated by thin lines.
|
|
Packaging of recombinant AAV.
DNA transfections were
performed by the calcium phosphate coprecipitation method essentially
as previously described (34). Briefly, 15 µg of
recombinant AAV plasmid (pCMVp-lacZ, pWP-8A, or pBK-2) and
15 µg of the AAV helper plasmid (pAAVp5, pAAV/Ad, or pSP-19) were
used per 15-cm-diameter dish of 70% confluent 293 cells. Eight hours
posttransfection, the medium was replaced with fresh medium containing
20 PFU of Ad2. The cultures were incubated at 37°C in a
CO2 incubator for 65 to 72 h, and cells were
harvested. The cell pellets were subjected to three cycles of freezing
and thawing. CsCl was added to a final density of 1.4 g/cm3
and centrifuged in an SW50.1 swinging-bucket rotor at 35,000 rpm for
48 h at 20°C. Fractions with refractive indices of 1.371 to
1.374 were pooled and dialyzed in 1× phosphate-buffered saline, followed by exhaustive digestion with DNase I. Clarified supernatants were heated at 56°C for 30 min to inactivate Ad2. Equivalent amounts were analyzed on quantitative DNA slot blots, using
32P-labeled DNA probes specific for wt AAV,
lacZ, or neo sequences as previously described
(22).
AAV DNA replication and amplification assays.
Approximately
70% confluent 293 cells in 10-cm-diameter dishes were coinfected with
recombinant AAV (multiplicity of infection of 10) and Ad2 (10 PFU). Seventy-two hours postinfection,
low-Mr DNA samples were isolated by the
procedure described by Hirt (13). Equivalent amounts of
low-Mr DNA, with or without prior digestion with
restriction endonucleases, were analyzed by Southern blotting using a
32P-labeled DNA probe specific for AAV coding sequences. To
amplify the replication-competent wt AAV in the recombinant
vector stocks, 293 cells were coinfected with recombinant AAV
(multiplicity of infection of 10) and Ad2 (10 PFU) as described above.
Seventy-two hours postinfection, cells were harvested and subjected to
three cycles of freezing and thawing. Clarified culture supernatants were used to infect 293 cells with 10 PFU of Ad2 again. This process was repeated for a total of four rounds.
Molecular cloning and sequencing of the wt AAV-like genomes.
After four rounds of amplification, the supernatants were used to
infect 293 cells with 10 PFU of Ad2. Low-Mr DNA
samples were isolated 72 h postinfection, digested with
restriction endonuclease BalI, and cloned into the
EcoRV site of plasmid pBluescript II SK(+). Bacterial
colonies containing plasmids with AAV sequences were selected by in
situ colony hybridization using 32P-labeled AAV DNA as a
probe. Nucleotide sequence analyses of each of the inserted full-length
AAV genomes were carried out with T3 and T7 primers as previously
described (50).
 |
RESULTS |
Contamination of the recombinant AAV vector stocks with wild-type
AAV-like particles.
Several groups have reported that recombinant
AAV stocks contain various levels of contaminating wild-type AAV
particles (11, 17, 21, 26, 33, 42). There are two possible
sources of this contamination. First, the helper adenovirus stocks may contain low levels of wt AAV, which is unlikely to be the case; second,
the contaminating AAV particles are not truly authentic AAV but are
generated by recombination events involving the recombinant AAV and the
helper plasmids. Indeed, wt AAV genomes present in the recombinant
vector stocks were not exactly like the wt AAV genome because of
differences in the patterns of hybridization following digestion
with various restriction endonucleases and Southern blot analyses. For
example, when recombinant vCMVp- lacZ vector
stocks, produced following cotransfection with plasmids pCMVp-lacZ and pAAVp5 and purified on CsCl gradients, were
used to infect Ad2-infected 293 cells and
low- Mr DNA were analyzed by using the AAV
right-end EcoRI-XbaI DNA fragment as a probe, the
results shown in Fig. 2a were obtained.
It is clear that the replicated AAV genomes could be digested with
restriction enzymes SacI, XbaI, and
BalI but not with ClaI. Based on these results, the following conclusions can be drawn. First, the recombinant AAV
vector preparations are free of the authentic wt AAV contamination since the wt AAV genome contains only one SacI site and no
XbaI sites; second, the contaminating AAV genomes are
derived from the helper plasmid since there are three SacI
and two XbaI sites in the helper plasmid (Fig. 2b), and
digestion with SacI or XbaI generated the DNA
fragments of the expected sizes. Thus, these contaminating AAV
particles are wt AAV-like particles.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
(a) Southern blot analyses for identification of
replication-competent wt AAV-like genomes. Following four rounds of
amplification, low-Mr DNA samples were digested
with the indicated restriction endonucleases and analyzed by Southern
blotting using the right half of the AAV DNA
(EcoRI-XbaI DNA fragment) probe. m and d denote
the monomeric and dimeric replicative forms of the AAV genome. (b)
Schematic representation of the AAV DNA replicative intermediates. The
expected approximate sizes of DNA fragments generated by enzymes
SacI (S), XbaI (X), BalI (B) from the
wt and the wt AAV-like DNA are indicated. The EcoRI
(E)-XbaI (X) DNA probe specific for the right-half of the
AAV genome from plasmid pSub201 is depicted as a thick line,
and AAV ITRs are shown as closed boxes.
|
|
Strategies for molecular cloning and sequencing of the wt AAV-like
genomes.
To investigate the mechanism of generation of these wt
AAV-like particles, it became necessary to characterize these genomes at the nucleotide sequence level. Figure
3 illustrates how these wt AAV-like
particles might be generated during recombinant AAV vector production
as well as the strategy to characterize these wt AAV-like genomes.
Briefly, following cotransfection of the recombinant AAV plasmid
containing a gene of interest and the AAV helper plasmid containing the
viral rep and cap genes in Ad2-infected 293 cells, most virions contain the recombinant AAV genome; however, a
small population of virions contain the wt AAV-like genome which is
comprised of AAV ITRs (derived from the recombinant AAV plasmid) and
the viral rep and cap genes (derived from the
helper plasmid), all of which are required for AAV replication and
encapsidation. The viral genomes were amplified following four rounds
of amplification in Ad2-infected 293 cells.
Low-Mr DNA samples were digested with BalI restriction endonuclease, which cleaves within the AAV
hairpin structure at nucleotide 121 in plasmid pSub201
(36), and molecularly cloned and sequenced as described in
Materials and Methods. BalI digestion of these
replication-competent AAV-like genomes would be expected to yield one
fragment containing the AAV D sequence and the putative recombination
junction sites since our previous studies have documented that the
first 10 nucleotides in the D sequence are required for high-efficiency
replication and encapsidation of the AAV genome (47-49).
Indeed, a single DNA fragment was detected on Southern blots following
digestion with BalI (Fig. 2a). A total of 24 recombinant
plasmids were sequenced, 22 of which contained intact AAV genomes.
These plasmids could be divided into six groups, A, B, C, D, E, and F,
the left and the right junction sequences from which are presented in
Fig. 4. The left junction in plasmids from group A contains the first 19 nucleotides of the D sequence and
the left end of the AAV genome. Based on the sequence, it is clear that
this genome is not the authentic wt AAV since it lacks the portion
between the D sequence and the AAV p5 promoter. The right junction in
plasmids from group A contains the same 19 nucleotides of the D
sequence, 30 additional nucleotides that match the left end of plasmids
from group A, and the right end of the helper plasmid. Thus, these wt
AAV-like particles contain all of the elements required for DNA
replication, such as the AAV ITR, as well as the rep and the
cap genes. Furthermore, these data suggest that the wt
AAV-like particles are generated by nonhomologous recombination between
the recombinant AAV plasmid and the helper plasmid. The 30 nucleotides
at the right end of plasmid A are derived from the left end of the
helper plasmid, which suggests that the recombination event first
occurred at the left end of the genome. The sequence at the right end
of plasmids from group A arose most probably from repair and/or
recombination between the left and the right ends of the recombinant
AAV genome and not from that between the recombinant AAV and the helper
plasmid DNA. In plasmids from group B, both ends contain the entire D sequence, but the recombination junctions between the AAV ITR derived
from the recombinant plasmid and the AAV genome derived from the helper
plasmid are completely different. Similarly, in plasmids from group C,
the left and right ends contain 17 and 19 nucleotides in the D
sequence, respectively, but the recombination junctions between the AAV
ITR and the AAV genome are totally different. These results suggest
that recombination events involving the left and right ends are
independent of each other. In plasmids from group D, the left end is
the same as the left end in plasmids from group A, but the right end is
different from the right end in plasmids from group A. In the plasmid
from group E, the left end is the same as the left end in plasmids from
group A, but the right end is the same as the right end in plasmids
from group C. In the plasmid from group F, the nucleotide sequence of
the left end is the same as that of the left end in plasmids from group
C, and the right end is the same as the right end in plasmids from
group B. The frequencies of these recombination events are presented in
Table 1. It appears that the Ra ITR is
repaired from the La ITR in approximately 9% of the clones. The
plasmid in group E is derived from recombination between plasmids in
groups A and C, and the plasmid in group F is derived from
recombination between plasmids in groups C and B, which together
constitute approximately 9% of the clones. However, in approximately
82% of the clones examined, the recombination event involving each ITR
occurs independently.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Experimental strategy for cloning the wt AAV-like
genomes from recombinant vector stocks. These particles generated
during the recombinant vector production are amplified through four
successive rounds of infection of adenovirus-infected 293 cells.
Low-Mr DNA is digested with restriction
endonuclease BalI, and DNA fragments are cloned in a
pBluescript SK(+) plasmid vector. AAV sequence-positive clones are
subjected to nucleotide sequencing using the T3 and T7 primers.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Nucleotide sequences of the left and right junctions
between AAV ITRs derived from the recombinant AAV-lacZ
vector and the AAV sequence derived from the helper plasmid (pAAVp5).
The D sequence, downstream from the BalI site (CCAA), is
shown in outline shadow font, and the AAV sequences from the helper
plasmid are shown in bold italic font. The sequence shown in outline
italic font in the right junction in plasmids in group A (Form Ra)
represents a duplication of the same sequence from the left junction
(Form La). The underlined nucleotide pairs indicate the recombination
junctions.
|
|
The recombination junctions are illustrated in Fig.
5, which indicates that most of the
recombination events are clustered
in the distal 10 nucleotides in the
D sequence. Interestingly,
however, there was no clear pattern of
recombination sites in
the AAV helper plasmid DNA (data not shown).
When the left junction
(form La) in plasmids from group A is compared
with the right
junction (form Rc) in plasmids from group C (Fig.
4),
the recombination
sites in the ITRs are the same but the rest of the
sequences are
different. Taken together, these data indicate that the
genesis
of wt AAV-like genomes is a consequence of multiple,
independent,
nonhomologous yet nonrandom recombination events involving
the
recombinant AAV and the helper plasmids as well as recombinant
AAV-like genomes.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 5.
Summary of nucleotide sequences of the left and the
right junctions in AAV ITRs from the recombinant AAV-lacZ
vector. The sequence at the top represents the AAV D sequence (outline
shadow font) downstream from the BalI site. The three left
and four right end sequences in the wt AAV-like genomes are shown in
the middle. The sequence at the bottom indicates the recombination
sites in AAV ITRs. The underlined nucleotides form the junctions, and
each asterisk represents the frequency of the recombination events.
|
|
Role of adenovirus ITRs in recombination.
To corroborate that
the distal 10 nucleotides in the D sequence were indeed the hot spots
for recombination, the wt AAV-like genomes amplified from a different
recombinant AAV vector (vTc.Neo) generated by cotransfection of the
recombinant AAV plasmid, pWP-8A, and a different AAV helper
plasmid, pAAV/Ad, were analyzed as described above except that
each of the ends was analyzed independently. The nucleotide sequences
of six left ends and three right ends of these genomes are presented in
Fig. 6. These data further provide strong
evidence that most of the recombination events involve the distal 10 nucleotides in the D sequence and that the recombination is
nonhomologous. Interestingly, however, upon closer examination, it
became evident that each of the junction sequences also contained the
Ad5 ITR sequences. The nucleotides in the Ad5 ITR sequence involved in
recombination events are highlighted in Fig.
7. When a helper plasmid that lacked the
Ad5 ITRs was used to generate recombinant AAV vectors, nearly a
fivefold reduction in the recombination frequency leading to generation
of wt AAV-like particles was observed. These data are summarized in
Fig. 8. Based on sequence analyses of 7 independent clones that were obtained with a helper plasmid that
contained Ad5 ITRs, there were five sites of recombination that led to
generation of biologically active wt AAV-like particles during
packaging of recombinant AAV, compared with 22 additional clones
generated with a helper plasmid that lacked the Ad5 ITRs in which there
were three sites of recombination. Similar results were obtained when
the extent of generation of wt AAV-like particles was determined by
quantitative DNA slot blot analyses (Table
2). Taken together, these results
demonstrate that the Ad5 ITRs play a role in illegitimate recombination
during the generation of the wt AAV-like particles.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 6.
Nucleotide sequences of the left and right junctions
between AAV ITRs from the recombinant vector pWP-8A and the AAV
sequence from the pAAV/Ad helper plasmid. The D sequence is shown in
outline shadow font, and the helper plasmid sequences are shown in bold
italic font. The underlined nucleotides indicate the recombination
junctions, and the asterisks represent the recombination frequency.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 7.
Nucleotide sequences of the junction fragments involving
the adenovirus ITRs. The adenovirus ITR sequence is shown in bold
italic font at the top. The sequence in the middle corresponds to the D
sequence downstream from the BalI site in the recombinant
AAV plasmid pWP-8A. The recombination sites in the Ad5 ITR sequences
are indicated by the underlined nucleotides. The asterisks represent
the recombination frequency.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 8.
Nucleotide sequence analyses of recombinant junctions in
the left ITR of the wt AAV-like genomes. The AAV D sequence, starting
with the BalI site (nucleotide 122) is shown in outline
font, and the rest of the AAV DNA sequence is shown in bold font.
+Ad5-ITR denotes the helper plasmid that contains the Ad5 ITRs
(pAAV/Ad), and Ad5-ITR denotes the helper plasmid that lacks the
Ad5-ITRs (pSP-19) which were used as helper plasmids to generate the
recombinant AAV vector stocks. The underlined nucleotides represent the
recombination sites, and the numbers indicate the observed frequency of
recombination events in 7 clones for the former and in 22 clones for
the latter that were analyzed.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Extent of contamination with the wt AAV-like physical
particles in vector stocks generated from various combinations of
recombinant and helper plasmids
|
|
Strategies for elimination of the wt AAV-like particles.
From
the foregoing, it stood to reason that removal of the distal 10 nucleotides in the D sequence from the recombinant AAV vector and
removal of the Ad5 ITRs from the AAV helper plasmid might prove
beneficial in substantially reducing, if not completely eliminating, the generation of the wt AAV-like particles during recombinant AAV vector production. This possibility was experimentally tested as follows. The potential hot spots of recombination were deleted in a recombinant AAV plasmid, pD-10 (Fig.
9), the construction of which has
recently been reported (49). This vector was used to
generate a recombinant AAV plasmid, pBK-2, containing the CMV promoter-driven lacZ gene. Four sets of recombinant
vCMVp-lacZ vector stocks were generated either with
pCMVp-lacZ (pD-20) or with pBK-2 (pD-10), with pAAV/Ad and
pSP-19 (prep/cap) as helper plasmids. Quantitative DNA slot
blot analysis of each of the stocks revealed that contamination with
the wt AAV-like genomes was highest in vectors generated from
pCMVp-lacZ plus pAAV/Ad and lowest in vectors generated from
pBK-2 plus pSP-19. These results, summarized in Table 2, suggest that
both adenovirus ITRs and the distal 10 nucleotides in the AAV-ITRs
promote the generation of the wt AAV-like particles. Equivalent amounts
of each of the vector stocks were also used to infect Ad2-infected 293 cells under identical conditions. Low-Mr DNA
isolated 72 h postinfection were analyzed by Southern blotting
using DNA probes specific for lacZ or AAV sequences,
respectively. These results are shown in Fig.
10. It is evident that the
lacZ probe detected the characteristic monomeric and dimeric
replicative forms of the recombinant AAV genomes, the hybridization
intensities of which were roughly the same in all vector preparations
(A). Interestingly, however, when a replicate Southern blot was probed
with the AAV probe, no AAV DNA replicative intermediates could be
detected in the recombinant AAV vector stocks prepared with plasmids
pBK-2 and pSP-19. The extent of generation of
replication-competent wt AAV-like particles was most pronounced
in recombinant vector stocks generated with pCMVp-lacZ plus pAAV/Ad, followed by that with pCMVp-lacZ plus
pSP-19 and pBK-2 plus pAAV/Ad (Fig. 10B). Even when the vector
stocks generated with plasmids pBK-2 and pSP-19 were amplified
through four successive rounds of amplification in Ad2-infected 293 cells, the AAV probe failed to detect any replication-competent wt
AAV-like particles, whereas abundant hybridization signals were
detected in vector stocks generated with plasmids
pCMVp-lacZ and pAAV/Ad even after one round of
amplification (Fig. 11). Although a low
level of wt AAV-like genomes was generated even in the absence of
adenovirus ITRs and the distal 10 nucleotides in the AAV D sequence
(Table 2), these genomes were replication incompetent (Fig. 10). Thus, these results corroborate our contention that removal of the distal 10 nucleotides in the D sequence from the recombinant AAV vector and
removal of the adenovirus ITRs from the AAV helper plasmid are
sufficient to eliminate generation of replication-competent wt AAV-like
particles during recombinant AAV vector production.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 9.
Schematic structures of pSub201 and pD-10
recombinant AAV vectors. The D sequence is shown as a shaded box in
plasmid pSub201. In plasmid pD-10, the distal 10 nucleotides
in the D sequence have been replaced by a substitute (S) sequence
described previously (47, 48). The relevant restriction
endonuclease sites (XbaI in pSub201 and
EcoRV in pD-10) for cloning a gene of interest are also
indicated. HP, hairpin.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 10.
Southern blot analyses of replication of the
recombinant AAV-lacZ and the wt AAV-like genomes generated
from recombinant plasmid pCMVp-lacZ (in pSub201)
or pBK-2 (CMVp-lacZ in pD-10) with a helper plasmid
containing (pAAV/Ad) or lacking (pSP-19) Ad5-ITRs, respectively.
Equivalent amounts of low-Mr DNA isolated at
72 h posttransfection from adenovirus-coinfected 293 cells were
analyzed by Southern blotting using lacZ-specific (A) and
AAV-specific (B) DNA probes. Autoradiography was performed for 48 h (A) and 4 days (B). m and d denote the monomeric and dimeric viral
replicative DNA intermediates, respectively.
|
|

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 11.
Southern blot analyses of replication of wt AAV-like
genomes present in recombinant vCMVp-lacZ vector stocks
generated from the recombinant AAV plasmid containing the entire D
sequence (pCMVp-lacZ) and the helper plasmid containing Ad5
ITRs (pAAV/Ad) (lanes 2, 5, 8, and 11) or from the recombinant AAV
plasmid containing deletions in the distal 10 nucleotides in the D
sequence (pBK-2) and the helper plasmid, pSP-19, lacking Ad5 ITRs
(pSP-19) (lanes 3, 6, 9, and 12). Equivalent amounts of
low-Mr DNA isolated at 72 h postinfection
from adenovirus-coinfected 293 cells were obtained following the
indicated rounds of amplification (1× to 4×) and analyzed by Southern
blotting using an AAV-specific DNA probe. In lanes 1, 4, 7, and 10, low-Mr DNA from mock-infected 293 cells were
analyzed. m and d denote the monomeric and dimeric replicative forms of
the AAV genome, respectively.
|
|
 |
DISCUSSION |
To obtain recombinant AAV vectors that are free of any
contaminating wt AAV, we must first understand the underlying molecular mechanism of generation of the wt AAV-like particles during recombinant AAV vector production. To this end, we considered the following three
approaches. The first approach was to purify these wt AAV-like particles, release the single-stranded virion DNA, anneal the single
strands, and molecularly clone the duplex DNA into plasmid vectors for
sequence analyses. This was not pursued given the extremely low titers
of wt AAV-like particles coupled with the potential difficulties in
cloning these intact genomes (35, 38). Some of these
difficulties included the complexity of AAV ITR structures, incomplete
reannealing, and the variability in junction sequences in the wt
AAV-like single-stranded genomes. The second approach was to resort to
amplification of the wt AAV-like genomes by PCR. This was also
considered less desirable since amplification of the
replication-defective genomes could not be circumvented, and both ends
of the wt AAV-like genomes could not be simultaneously analyzed
(1). We devised a third approach in which the
replication-competent replicative DNA intermediates of wt AAV-like
genomes were cloned into a plasmid and subjected to nucleotide sequence
analyses. The use of restriction enzyme BalI ensured that
both monomeric and dimeric replicative forms would be represented and
that the cloning step would be more efficient since the bulk of the AAV
ITRs would be excluded, leading to simultaneous analyses of both ends
of the viral genomes. However, a number of inherent experimental
restrictions could not be overcome. For example, in order to be cloned
and analyzed, AAV DNA intermediates must be digestable with
BalI. In order to be amplified, recombinants must be
efficiently rescued and packaged, eliminating ITR and proximal
D-sequence mutations. Furthermore, since all recombinants are unlikely
to replicate at the same rate, there might be preferential selection of
those species that replicate more efficiently. And finally, since
rep and cap gene functions can be provided in
trans, mixtures of recombinants could be generated in which
otherwise defective mutants could trans-complement another.
Previous studies have documented that significant sequence homology
between the recombinant AAV plasmid and the helper plasmid leads to
replication-competent wt AAV (26). To eliminate this problem, Samulski et al. (37) subsequently developed the
pSub201-pAAV/Ad packaging system in which all homologous
sequences between the two plasmids were deleted. However, despite this
advance, we (21, 33) and others (11, 17, 26, 42)
have consistently detected the presence of wt AAV sequences, ranging
between 0.01 and 10%, in recombinant AAV vector stocks. Extensive
sequence analyses of the recombination junctions in the present study
revealed that the wt AAV-like particles are generated by nonhomologous
recombination.
The presence of Ad5 ITRs in the helper plasmid seemed to promote
recombination between the recombinant AAV and the helper plasmids.
There are two stretches of homology between Ad5 ITR and AAV ITR
sequences (AGGGG and GGGGT), but only the latter was involved in only
one of the clones examined. Additional stretches of homology between
the Ad5 ITR and the noncoding sequences in the recombinant AAV
plasmid, pWP-8A, also exist (TCATC, TTAT, TAATGA, AGTTT, and
GGGAA [Fig. 7]); however, most of the recombination sites share
either no homology or only one or two nucleotides between these
sequences. These data suggest that for the most part, four to six
nucleotides are not sufficient to mediate homologous recombination
between the two plasmid sequences. Thus, we conclude that the observed
recombination events are illegitimate. Although remarkably similar
observations have recently been made by Allen et al. (1),
these authors examined only six clones (four from the left end and two
from the right end) generated by PCR amplification, which would not
discriminate between replication-competent and replication-defective wt
AAV-like genomes. Furthermore, the two ends of the viral genomes were
analyzed independently. In contrast, we examined recombination
junctions at both ends simultaneously in a substantially larger
population (22 clones) of replication-competent wt AAV-like genomes in
our studies. Our data also indicate that most of the recombination
events involve the distal 10 nucleotides in the D sequence. It is
likely that recombination events occur in the proximal 10 nucleotides
in the D sequence as well, but since the first 10 nucleotides of the D
sequence are indispensable for replication and encapsidation of the AAV
genome (47-49, 51), we surmise that such recombination
events lead to production of replication-defective wt AAV-like
particles.
A number of approaches have been used to obtain wt AAV-free stocks of
recombinant AAV vectors (1, 9, 37, 46). Our studies
offer a relatively simple strategy to achieve the same objective.
Although we did not detect significant differences in the recombinant
viral titers when helper plasmids either contain the Ad5 ITRs or lack
them (Table 2), we suggest that it might be prudent to avoid the use of
a helper plasmid that contains adenovirus ITRs to minimize generation
of wt AAV-like particles. Furthermore, since removal of the distal
10 nucleotides in the D sequence from the next generation of
pD- 10- based recombinant AAV vectors leads to complete
elimination of replication-competent wt AAV-like particles, when a
helper plasmid lacking adenovirus ITRs is used, such a combined
approach should be useful in generating clinical-grade vectors for
human gene therapy.
 |
ACKNOWLEDGMENTS |
We thank Richard J. Samulski for providing plasmid pAAV/Ad.
This research was supported in part by Public Health Service grants
(HL-48342, HL-53586, HL-58881, and DK-49218; Centers for Excellence in
Molecular Hematology) from the National Institutes of Health and a
grant from the Phi Beta Psi Sorority. A.S. was supported by an
Established Investigator Award from the American Heart Association.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, 635 Barnhill Dr., Medical Science Building Room 231-B, Indiana University School of Medicine, Indianapolis, IN
46202-5120. Phone: (317) 274-2194. Fax: (317) 274-4090. E-mail: asrivast{at}iupui.edu.
 |
REFERENCES |
| 1.
|
Allen, J. M.,
D. J. Debelak,
T. C. Reynolds, and A. D. Miller.
1997.
Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by non-homologous recombination during AAV vector production.
J. Virol.
71:6816-6822[Abstract].
|
| 2.
|
Ashktorab, H., and A. Srivastava.
1989.
Identification of nuclear proteins that specifically interact with adeno-associated virus type 2 inverted terminal repeat hairpin DNA.
J. Virol.
63:3034-3039[Abstract/Free Full Text].
|
| 3.
|
Berns, K. I., and R. A. Bohenzky.
1987.
Adeno-associated viruses: an update.
Adv. Virus Res.
32:243-306[Medline].
|
| 4.
|
Berns, K. I., and C. Giraud.
1996.
Biology of adeno-associated virus.
Curr. Top. Microbiol. Immunol.
218:1-23[Medline].
|
| 5.
|
Berns, K. I.,
R. M. Kotin, and M. A. Labow.
1988.
Regulation of adeno-associated virus DNA replication.
Biochim. Biophys. Acta
951:425-429[Medline].
|
| 6.
|
Chejanovsky, N., and B. J. Carter.
1989.
Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication.
Virology
173:120-128[Medline].
|
| 7.
|
Chiorini, J. A.,
S. M. Wiener,
L. Yang,
R. H. Smith,
B. Safer,
N. P. Kilcoin,
Y. Liu,
E. Urcelay, and R. M. Kotin.
1996.
The roles of AAV Rep proteins in gene expression and targeted integration.
Curr. Top. Microbiol. Immunol.
218:25-33[Medline].
|
| 8.
|
Flotte, T. R.,
S. A. Afione, and P. L. Zeitlin.
1994.
Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration.
Am. J. Respir. Cell Mol. Biol.
11:517-521[Abstract].
|
| 9.
|
Flotte, T. R., and B. J. Carter.
1995.
Adeno-associated virus vectors for gene therapy.
Gene Ther.
2:357-362[Medline].
|
| 10.
|
Giraud, C.,
E. Winocour, and K. I. Berns.
1995.
Recombinant junctions formed by site-specific integration of adeno-associated virus genome into an episome.
J. Virol.
69:6917-6924[Abstract].
|
| 11.
|
Hargrove, P. W.,
E. F. Vanin,
G. J. Kurtzman, and A. W. Nienhuis.
1997.
High-level globin expression mediated by a recombinant adeno-associated virus genome that contains the 3' -globin gene regulatory element and integrates as tandem copies in erythroid cells.
Blood
89:2167-2175[Abstract/Free Full Text].
|
| 12.
|
Hauswirth, W. W., and K. I. Berns.
1977.
Origin and termination of adeno-associated virus DNA replication.
Virology
78:488-499[Medline].
|
| 13.
|
Hirt, B.
1967.
Selective extraction of polyoma DNA from infected mouse cell cultures.
J. Mol. Biol.
26:365-369[Medline].
|
| 14.
|
Im, D.-S., and N. Muzyczka.
1989.
Factors that bind to adeno-associated virus terminal repeats.
J. Virol.
63:3095-3104[Abstract/Free Full Text].
|
| 15.
|
Im, D.-S., and N. Muzyczka.
1990.
The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity.
Cell
61:447-457[Medline].
|
| 16.
|
Im, D.-S., and N. Muzyczka.
1992.
Partial purification of adeno-associated virus Rep78, Rep68, Rep52, and Rep40 proteins and their biochemical characterization.
J. Virol.
66:1119-1128[Abstract/Free Full Text].
|
| 17.
|
Koeberl, D. D.,
I. E. Alexander,
C. L. Halbert,
D. W. Russell, and A. D. Miller.
1997.
Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.
Proc. Natl. Acad. Sci. USA
94:1426-1431[Abstract/Free Full Text].
|
| 18.
|
Kotin, R. M., and K. I. Berns.
1989.
Organization of adeno-associated virus DNA in latently infected Detroit 6 cells.
Virology
170:460-467[Medline].
|
| 19.
|
Kotin, R. M.,
J. C. Menninger,
D. C. Ward, and K. I. Berns.
1991.
Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter.
Genomics
10:831-834[Medline].
|
| 20.
|
Kotin, R. M.,
M. Siniscalco,
R. J. Samulski,
X. Zhu,
L. Hunter,
C. A. Laughlin,
S. McLaughlin,
N. Muzyczka,
M. Rocchi, and K. I. Berns.
1990.
Site-specific integration by adeno-associated virus.
Proc. Natl. Acad. Sci. USA
87:2211-2215[Abstract/Free Full Text].
|
| 21.
|
Kube, D. M.,
S. Ponnazhagan, and A. Srivastava.
1997.
Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells.
J. Virol.
71:7361-7371[Abstract].
|
| 22.
|
Kube, D. M., and A. Srivastava.
1997.
Quantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions.
Nucleic Acids Res.
25:3375-3376[Abstract/Free Full Text].
|
| 23.
|
Lusby, E.,
K. H. Fife, and K. I. Berns.
1980.
Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA.
J. Virol.
34:402-409[Abstract/Free Full Text].
|
| 24.
|
McCarty, D. M.,
D. J. Pereira,
I. Zolotukhin,
X. Zhou,
J. H. Ryan, and N. Muzyczka.
1994.
Identification of linear DNA sequences that specifically bind the adeno-associated virus rep protein.
J. Virol.
68:4988-4997[Abstract/Free Full Text].
|
| 25.
|
McCarty, D. M.,
J. H. Ryan,
S. Zolotukhin,
X. Zhou, and N. Muzyczka.
1994.
Interaction of the adeno-associated virus rep protein with a sequence within the palindrome of the viral terminal repeat.
J. Virol.
68:4998-5006[Abstract/Free Full Text].
|
| 26.
|
Muzyczka, N.
1992.
Use of adeno-associated virus as a general transduction vector for mammalian cells.
Curr. Top. Microbiol. Immunol.
158:97-129[Medline].
|
| 27.
|
Nahreini, P., and A. Srivastava.
1989.
Rescue and replication of the adeno-associated virus 2 genome in mortal and immortal human cells.
Intervirology
30:74-85[Medline].
|
| 28.
|
Nahreini, P., and A. Srivastava.
1992.
Rescue of the adeno-associated virus 2 genome correlates with alterations in DNA-modifying enzymes in human cells.
Intervirology
33:109-115[Medline].
|
| 29.
|
Nahreini, P.,
M. J. Woody,
S. Z. Zhou, and A. Srivastava.
1993.
Versatile adeno-associated virus 2-based vectors for constructing recombinant virions.
Gene
124:257-262[Medline].
|
| 30.
|
Podsakoff, G.,
K. K. Wong, Jr., and S. Chatterjee.
1994.
Stable and efficient gene transfer into nondividing cells by adeno-associated virus-based vectors.
J. Virol.
68:5656-5666[Abstract/Free Full Text].
|
| 31.
|
Ponnazhagan, S.,
P. Mukherjee,
M. C. Yoder,
X.-S. Wang,
S. Z. Zhou,
J. Kaplan,
S. Wadsworth, and A. Srivastava.
1997.
Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice.
Gene
190:203-210[Medline].
|
| 32.
|
Ponnazhagan, S.,
X.-S. Wang,
M. J. Woody,
F. Luo,
L. Y. Kang,
M. L. Nallari,
N. C. Munshi,
S. Z. Zhou, and A. Srivastava.
1996.
Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukemia cells are non-permissive for AAV infection.
J. Gen. Virol.
77:1111-1122[Abstract/Free Full Text].
|
| 33.
|
Ponnazhagan, S.,
M. C. Yoder, and A. Srivastava.
1997.
Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo.
J. Virol.
71:3098-3104[Abstract].
|
| 34.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
In
Molecular cloning: a laboratory manual, 2nd ed., p. 1.53-1.110.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 35.
|
Samulski, R. J.,
K. I. Berns,
M. Tan, and N. Muzyczka.
1982.
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells.
Proc. Natl. Acad. Sci. USA
79:2077-2081[Abstract/Free Full Text].
|
| 36.
|
Samulski, R. J.,
L.-S. Chang, and T. Shenk.
1987.
A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.
J. Virol.
61:3096-3101[Abstract/Free Full Text].
|
| 37.
|
Samulski, R. J.,
L.-S. Chang, and T. Shenk.
1989.
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.
J. Virol.
63:3822-3828[Abstract/Free Full Text].
|
| 38.
|
Samulski, R. J.,
A. Srivastava,
K. I. Berns, and N. Muzyczka.
1983.
Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV.
Cell
33:135-143[Medline].
|
| 39.
|
Samulski, R. J.,
X. Zhu,
X. Xiao,
J. Brook,
D. E. Houseman,
N. Epstein, and L. A. Hunter.
1991.
Targeted integration of adeno-associated virus (AAV) into human chromosome 19.
EMBO J.
10:3941-3950[Medline].
|
| 40.
|
Senapathy, P.,
J.-D. Tratschin, and B. J. Carter.
1984.
Replication of adeno-associated virus DNA. Complementation of naturally occurring rep mutants by a wild-type genome or an ori mutant and correction of terminal palindrome deletions.
J. Mol. Biol.
179:1-20[Medline].
|
| 41.
|
Shaughnessy, E.,
D. Lu,
S. Chatterjee, and K. K. Wong, Jr.
1996.
Parvoviral vectors for the gene therapy of cancer.
Semin. Oncol.
23:159-171[Medline].
|
| 42.
|
Snyder, R. O.,
C. H. Miao,
G. A. Patijn,
K. Spratt,
O. Danos,
D. Nagy,
A. M. Gown,
B. Winther,
L. Meuse,
L. K. Cohen,
A. R. Thompson, and M. A. Kay.
1997.
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Nat. Genet.
16:270-276[Medline].
|
| 43.
|
Srivastava, A.
1987.
Replication of the adeno-associated virus DNA termini in vitro.
Intervirology
27:138-147[Medline].
|
| 44.
|
Srivastava, A.
1994.
Parvovirus-based vectors for human gene therapy.
Blood Cells
20:531-536[Medline].
|
| 44a.
|
Srivastava, A.
1998.
Delivery system for gene therapy: adeno-associated virus 2, p. 257-288.
In
P. J. Quesenberry, G. S. Stein, B. Forget, and S. Weissman (ed.), Stem cell biology and gene therapy. Wiley-Liss, Inc., New York, N.Y.
|
| 45.
|
Srivastava, A.,
E. W. Lusby, and K. I. Berns.
1983.
Nucleotide sequence and organization of the adeno-associated virus 2 genome.
J. Virol.
45:555-564[Abstract/Free Full Text].
|
| 46.
|
Vincent, K. A.,
S. T. Piraino, and S. C. Wadsworth.
1997.
Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products.
J. Virol.
71:1897-1905[Abstract].
|
| 47.
|
Wang, X.-S.,
S. Ponnazhagan, and A. Srivastava.
1995.
Rescue and replication signals of the adeno-associated virus 2 genome.
J. Mol. Biol.
250:573-580[Medline].
|
| 48.
|
Wang, X.-S.,
S. Ponnazhagan, and A. Srivastava.
1996.
Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions.
J. Virol.
70:1668-1677[Abstract].
|
| 49.
|
Wang, X.-S.,
K. Y. Qing,
S. Ponnazhagan, and A. Srivastava.
1997.
Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats.
J. Virol.
71:3077-3082[Abstract].
|
| 50.
|
Wang, X.-S., and A. Srivastava.
1997.
A novel terminal resolution-like site in the adeno-associated virus type 2 genome.
J. Virol.
71:1140-1146[Abstract].
|
| 51.
|
Wang, X.-S., and A. Srivastava.
1998.
Rescue and autonomous replication of adeno-associated virus type 2 genomes containing Rep-binding site mutations in the viral p5 promoter.
J. Virol.
72:4811-4818[Abstract/Free Full Text].
|
J Virol, July 1998, p. 5472-5480, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nony, P., Chadeuf, G., Tessier, J., Moullier, P., Salvetti, A.
(2002). Evidence for Packaging of rep-cap Sequences into Adeno-Associated Virus (AAV) Type 2 Capsids in the Absence of Inverted Terminal Repeats: a Model for Generation of rep-Positive AAV Particles. J. Virol.
77: 776-781
[Abstract]
[Full Text]
-
Qiao, C., Wang, B., Zhu, X., Li, J., Xiao, X.
(2002). A Novel Gene Expression Control System and Its Use in Stable, High-Titer 293 Cell-Based Adeno-Associated Virus Packaging Cell Lines. J. Virol.
76: 13015-13027
[Abstract]
[Full Text]
-
Hansen, J., Qing, K., Srivastava, A.
(2001). Adeno-Associated Virus Type 2-Mediated Gene Transfer: Altered Endocytic Processing Enhances Transduction Efficiency in Murine Fibroblasts. J. Virol.
75: 4080-4090
[Abstract]
[Full Text]
-
Cao, L., Liu, Y., During, M. J., Xiao, W.
(2000). High-Titer, Wild-Type Free Recombinant Adeno-Associated Virus Vector Production Using Intron-Containing Helper Plasmids. J. Virol.
74: 11456-11463
[Abstract]
[Full Text]
-
Mah, C., Qing, K., Khuntirat, B., Ponnazhagan, S., Wang, X.-S., Kube, D. M., Yoder, M. C., Srivastava, A.
(1998). Adeno-Associated Virus Type 2-Mediated Gene Transfer: Role of Epidermal Growth Factor Receptor Protein Tyrosine Kinase in Transgene Expression. J. Virol.
72: 9835-9843
[Abstract]
[Full Text]